Weight loss jabs can ease symptoms of a common skin condition, new research suggests.
Hidradenitis Suppurative (HS) is a chronic condition which can lead to abscesses and scarring, affecting around on in 100 people.
Treatment with semaglutide – the key ingredient in Wegovy and Ozempic – was found to significantly reduce painful flare-ups.
Obese patients who had varying levels of HS were given a weekly jab at low average dose of 0.8mg for around eight months.
Researchers monitored changes in body mass index (BMI), weight, flare frequency, pain and Dermatology Life Quality Index (DLQI) – a score used to assess the overall impact of symptoms.
They also looked at biochemical markers, including blood sugar and C-reactive protein (CRP) levels, a measure of inflammation.
Typically, flare-ups reduce from once every 8.5 weeks to once every three months, according to the findings presented at the European Academy of Dermatology and Venereology (EADV) Congress
Quality of life also improved significantly, reflected in a reduction of the DLQI score from an average of 13/30 to 9/30.
Notably, one-third of patients achieved a DLQI score reduction of four points or more, equalling or surpassing the minimally important differences for this index.
Dr Daniel Lyons, lead researcher from St Vincent’s University Hospital, Dublin, Ireland, said the findings show modes doses can offer substantial benefits in managing HS.
He said: ‘While the drug’s role in promoting weight loss is well-established, what’s particularly exciting is its potential to also reduce the frequency of HS flare-ups, contributing to the notable improvements observed in patients’ quality of life.
‘The results are highly encouraging and could represent a major breakthrough in HS treatment.’
The improvements to skin health are the latest in a long line of benefits linked to these drugs, known as GLP-1 agonists, which mimic a hormone that help people feel full for longer and lowers blood sugars.
In addition to weight loss, it has been found to slash the chances of heart attack and stroke, kidney disease and even slow the ageing process.
Scientists believe these widespread health benefits are caused by its ability to reduce levels of inflammation, seen in many chronic conditions.
The exact cause of HS is unknown but the condition is more common in women, occurring near hair follicles where there are sweat glands, such as around breasts and armpits.
The condition tends to start with blackheads, spots filled with pus and firm pea-sized lumps that develop in one place and rupture.
Researchers hope to build on results from this trial involving 30 patients to include larger numbers of patients.
Dr Lyons added: ‘Ultimately, we hope our preliminary data will encourage dermatologists to consider weight loss medication as an adjunct to existing HS treatments and inspire further research in this area aimed at improving outcomes for people living with this challenging condition.'
